Journal article

A Genome-Wide Association Study of Neuroticism in a Population-Based Sample

Federico CF Calboli, Federica Tozzi, Nicholas W Galwey, Athos Antoniades, Vincent Mooser, Martin Preisig, Peter Vollenweider, Dawn Waterworth, Gerard Waeber, Michael R Johnson, Pierandrea Muglia, David J Balding

PLOS ONE | PUBLIC LIBRARY SCIENCE | Published : 2010

Abstract

Neuroticism is a moderately heritable personality trait considered to be a risk factor for developing major depression, anxiety disorders and dementia. We performed a genome-wide association study in 2,235 participants drawn from a population-based study of neuroticism, making this the largest association study for neuroticism to date. Neuroticism was measured by the Eysenck Personality Questionnaire. After Quality Control, we analysed 430,000 autosomal SNPs together with an additional 1.2 million SNPs imputed with high quality from the Hap Map CEU samples. We found a very small effect of population stratification, corrected using one principal component, and some cryptic kinship that requir..

View full abstract

University of Melbourne Researchers

Grants

Awarded by Swiss National Science Foundation


Funding Acknowledgements

The PsyCoLaus study was supported by grants from the Swiss National Science Foundation (#3200B0-105993, #3200B0-118308, 33CSCO-122661) and from GlaxoSmithKline (Psychiatry Center of Excellence for Drug Discovery and Genetics Division, Drug Discovery - Verona, R&D). F. Calboli was supported by a GSK grant to Imperial College London. GlaxoSmithKline had a role in study design, data analysis, decision to publish, and preparation of the manuscript: F. Tozzi, V. Mooser, D. Waterworth and N. W. Galwey are GlaxoSmithKline full-time employees. P. Muglia was a GlaxoSmithKline full-time employee at the time when this study was performed. M. Johnson was a GSK consultant at the time when the project was initiated.The authors would like to express their gratitude to the Lausanne inhabitants who volunteered to participate in the PsyCoLaus study. We would also like to thank all the CoLaus investigators, and the PsyColaus investigators who have contributed to the recruitment, Marie-Louise Matthey, Christiane Shalofsky, Georgette Jungo, Stephane Rothen, Lajos Oros and Gioia Roccia, as well as many GSK employees who contributed to the execution of this study including Alun McCarthy, Paul Matthews, and especially Emiliangelo Ratti for supporting this work within GSK Drug Discovery. Special thanks also go to Allen Roses and Lefkos Middleton. Thanks to William Astle for providing code and assistance for the mixed-model analysis.